Injectable HIV prevention drug for people who inject drugs
Part of Mental health clinical trials.
This study tests a long-acting injectable medication called cabotegravir to prevent HIV in people who inject drugs. If you have injected street drugs recently, you may be able to get this shot every few months instead of taking daily pills.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have injected drugs that were not prescribed by a doctor within the last 6 months
- You do not have HIV (you'll be tested)
- You have never used cabotegravir before
- You are not pregnant or breastfeeding
- You are not taking any of these medicines: carbamazepine, rifampin, oxcarbazepine, rifapentine, phenobarbital, or phenytoin
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study offers a new injectable medication called lenacapavir to prevent HIV. It is for people who are HIV-negative and sexually active, and want to try a long-acting injection instead of daily pills.
This study tests how a long-acting injectable HIV prevention drug (cabotegravir) works in people who also use hormone therapy (like birth control or gender-affirming hormones). The goal is to see if the hormones affect how well the drug prevents HIV. If you are HIV-negative, use hormones, and meet other health criteria, you may be able to join.
This Phase 3 study tests whether an injectable HIV prevention medicine (cabotegravir) given before exposure can help prevent HIV in people at higher risk. You may join if you are HIV-negative and meet specific sexual health, medication, and health-testing requirements.
This study tests a long-acting HIV prevention shot (Cabotegravir) or a vaginal ring (DapiRing) along with sexual health services for young people. It aims to find the best way to prevent HIV and support overall health.
This trial tests a long-acting injectable form of HIV prevention (cabotegravir) vs. continuing daily PrEP pills. It is for cisgender men in France who have sex with men and have already been using PrEP for at least 6 months.
This trial looks at how well a daily HIV-prevention pill (F/TAF) works in people who use drugs. The goal is to understand real-world effectiveness and help support people in staying HIV-negative.
Hear when a new HIV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.